Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only
Androgen deprivation is a common treatment option in patients with locally advanced or metastatic prostate cancer. No case of long term treatment with an intermittent approach with only low dose bicalutamide (50 mg daily) has been described yet. We report a 60-year-old patient, initially presenting...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Urology |
| Online Access: | http://dx.doi.org/10.1155/2015/928787 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549887338610688 |
|---|---|
| author | Stefan Latz Christian Fisang Wolfram Ebert Stefan Orth Dirk G. Engehausen Stefan C. Müller Ralf Anding |
| author_facet | Stefan Latz Christian Fisang Wolfram Ebert Stefan Orth Dirk G. Engehausen Stefan C. Müller Ralf Anding |
| author_sort | Stefan Latz |
| collection | DOAJ |
| description | Androgen deprivation is a common treatment option in patients with locally advanced or metastatic prostate cancer. No case of long term treatment with an intermittent approach with only low dose bicalutamide (50 mg daily) has been described yet. We report a 60-year-old patient, initially presenting with a PSA elevation of 19.2 ng/mL in 1996. After diagnosis of well to moderately differentiated prostate cancer by transrectal biopsy, the patient underwent an open radical prostatectomy. Final diagnosis was adenocarcinoma of the prostate, classified as pT3a, pR1, pV0, and pL1. Adjuvant intermittent androgen deprivation therapy with flutamide 250 mg was applied, which was changed to bicalutamide 50 mg once daily when it became available in 2001. Six on-phases were performed and PSA values never exceeded 20 ng/mL. The patient did not experience any serious side effects. To date, there are no clinical or radiological signs of progression. Current PSA value is 3.5 ng/mL. |
| format | Article |
| id | doaj-art-cb0b47285d5040aa89349677c2c7d19f |
| institution | Kabale University |
| issn | 2090-696X 2090-6978 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Urology |
| spelling | doaj-art-cb0b47285d5040aa89349677c2c7d19f2025-02-03T06:08:23ZengWileyCase Reports in Urology2090-696X2090-69782015-01-01201510.1155/2015/928787928787Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide OnlyStefan Latz0Christian Fisang1Wolfram Ebert2Stefan Orth3Dirk G. Engehausen4Stefan C. Müller5Ralf Anding6Department of Urology, University Hospital Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, GermanyDepartment of Urology, University Hospital Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, GermanyDepartment of Urology, Kreiskrankenhaus Luedenscheid, Paulmannshöher Straße 14, 58515 Luedenscheid, GermanyDepartment of Urology, Klinikum-Westfalen GmbH, Am Knappschaftskrankenhaus 1, 44309 Dortmund, GermanyDepartment of Urology, University Hospital Erlangen, Krankenhausstraße 12, 91054 Erlangen, GermanyDepartment of Urology, University Hospital Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, GermanyDepartment of Urology, University Hospital Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, GermanyAndrogen deprivation is a common treatment option in patients with locally advanced or metastatic prostate cancer. No case of long term treatment with an intermittent approach with only low dose bicalutamide (50 mg daily) has been described yet. We report a 60-year-old patient, initially presenting with a PSA elevation of 19.2 ng/mL in 1996. After diagnosis of well to moderately differentiated prostate cancer by transrectal biopsy, the patient underwent an open radical prostatectomy. Final diagnosis was adenocarcinoma of the prostate, classified as pT3a, pR1, pV0, and pL1. Adjuvant intermittent androgen deprivation therapy with flutamide 250 mg was applied, which was changed to bicalutamide 50 mg once daily when it became available in 2001. Six on-phases were performed and PSA values never exceeded 20 ng/mL. The patient did not experience any serious side effects. To date, there are no clinical or radiological signs of progression. Current PSA value is 3.5 ng/mL.http://dx.doi.org/10.1155/2015/928787 |
| spellingShingle | Stefan Latz Christian Fisang Wolfram Ebert Stefan Orth Dirk G. Engehausen Stefan C. Müller Ralf Anding Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only Case Reports in Urology |
| title | Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only |
| title_full | Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only |
| title_fullStr | Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only |
| title_full_unstemmed | Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only |
| title_short | Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only |
| title_sort | long term progression free survival in a patient with locally advanced prostate cancer under low dose intermittent androgen deprivation therapy with bicalutamide only |
| url | http://dx.doi.org/10.1155/2015/928787 |
| work_keys_str_mv | AT stefanlatz longtermprogressionfreesurvivalinapatientwithlocallyadvancedprostatecancerunderlowdoseintermittentandrogendeprivationtherapywithbicalutamideonly AT christianfisang longtermprogressionfreesurvivalinapatientwithlocallyadvancedprostatecancerunderlowdoseintermittentandrogendeprivationtherapywithbicalutamideonly AT wolframebert longtermprogressionfreesurvivalinapatientwithlocallyadvancedprostatecancerunderlowdoseintermittentandrogendeprivationtherapywithbicalutamideonly AT stefanorth longtermprogressionfreesurvivalinapatientwithlocallyadvancedprostatecancerunderlowdoseintermittentandrogendeprivationtherapywithbicalutamideonly AT dirkgengehausen longtermprogressionfreesurvivalinapatientwithlocallyadvancedprostatecancerunderlowdoseintermittentandrogendeprivationtherapywithbicalutamideonly AT stefancmuller longtermprogressionfreesurvivalinapatientwithlocallyadvancedprostatecancerunderlowdoseintermittentandrogendeprivationtherapywithbicalutamideonly AT ralfanding longtermprogressionfreesurvivalinapatientwithlocallyadvancedprostatecancerunderlowdoseintermittentandrogendeprivationtherapywithbicalutamideonly |